A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis
Latest Information Update: 01 Dec 2023
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 25 Aug 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 30 Jun 2021 to 31 Jul 2021.
- 10 Dec 2019 Results assessing burden of cereblon mutation or transcript variants in relapsed refractory myeloma patients by using data from four studies including this study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.